These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3881051)

  • 41. Oral physostigmine and lecithin improve memory in Alzheimer's disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS; Davies P
    Psychopharmacol Bull; 1983; 19(3):454-6. PubMed ID: 6635124
    [No Abstract]   [Full Text] [Related]  

  • 42. Oral physostigmine in Alzheimer's disease.
    Davis KL; Mohs RC; Davis BM; Horvath TB; Greenwald BS; Rosen WG; Levy MI; Johns CA
    Psychopharmacol Bull; 1983; 19(3):451-3. PubMed ID: 6635123
    [No Abstract]   [Full Text] [Related]  

  • 43. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
    Mandel RJ; Chen AD; Connor DJ; Thal LJ
    J Pharmacol Exp Ther; 1989 Nov; 251(2):612-9. PubMed ID: 2810114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration.
    Becker R; Giacobini E; Elble R; McIlhany M; Sherman K
    Acta Neurol Scand Suppl; 1988; 116():19-32. PubMed ID: 3043998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Animal models of Alzheimer's disease: behavior, pharmacology, transplants.
    Haroutunian V; Kanof PD; Tsuboyama GK; Campbell GA; Davis KL
    Can J Neurol Sci; 1986 Nov; 13(4 Suppl):385-93. PubMed ID: 2878711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease.
    Pomara N; Domino EF; Yoon H; Brinkman S; Tamminga CA; Gershon S
    J Clin Psychiatry; 1983 Aug; 44(8):293-5. PubMed ID: 6874650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease.
    Levin HS; Peters BH
    Ann Neurol; 1984 Feb; 15(2):210. PubMed ID: 6703661
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.
    Muramoto O; Sugishita M; Sugita H; Toyokura Y
    Arch Neurol; 1979 Aug; 36(8):501-3. PubMed ID: 508162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease.
    Thal LJ; Masur DM; Sharpless NS; Fuld PA; Davies P
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):627-36. PubMed ID: 3797688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Physostigmine and its effect on six patients with dementia.
    Ashford JW; Soldinger S; Schaeffer J; Cochran L; Jarvik LF
    Am J Psychiatry; 1981 Jun; 138(6):829-30. PubMed ID: 7246817
    [No Abstract]   [Full Text] [Related]  

  • 53. Transdermal physostigmine in the treatment of Alzheimer's disease.
    Levy A; Brandeis R; Treves TA; Meshulam Y; Mawassi F; Feiler D; Wengier A; Glikfeld P; Grunwald J; Dachir S
    Alzheimer Dis Assoc Disord; 1994; 8(1):15-21. PubMed ID: 8185877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia.
    Caltagirone C; Albanese A; Gainotti G; Masullo C
    Int J Neurosci; 1983; 18(1-2):143-7. PubMed ID: 6840979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parasympathetic suppression of manic symptoms by physostigmine.
    Janowsky DS; el-Yousef K; Davis JM; Sekerke HJ
    Arch Gen Psychiatry; 1973 Apr; 28(4):542-7. PubMed ID: 4692153
    [No Abstract]   [Full Text] [Related]  

  • 57. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
    Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
    Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physostigmine in mania.
    Davis KL; Berger PA; Hollister LE; Defraites E
    Arch Gen Psychiatry; 1978 Jan; 35(1):119-22. PubMed ID: 339869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective changes in sensitivity to cholinergic agonists and receptor changes elicited by continuous physostigmine infusion.
    Bhat RV; Turner SL; Marks MJ; Collins AC
    J Pharmacol Exp Ther; 1990 Oct; 255(1):187-96. PubMed ID: 2213555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.